Loureirin C inhibits ferroptosis and apoptosis in 6-OHDA-induced Parkinson's model

IF 2.7 4区生物学 Q1 ANATOMY & MORPHOLOGY Tissue & cell Pub Date : 2025-01-08 DOI:10.1016/j.tice.2025.102721

Zhongmei Chen , Ruimin Hou , Yuping Zhang , Mingjian Xiong , Dongping Zhang , Chawen Ding

{"title":"Loureirin C inhibits ferroptosis and apoptosis in 6-OHDA-induced Parkinson's model","authors":"Zhongmei Chen , Ruimin Hou , Yuping Zhang , Mingjian Xiong , Dongping Zhang , Chawen Ding","doi":"10.1016/j.tice.2025.102721","DOIUrl":null,"url":null,"abstract":"<div><div>Parkinson's disease (PD) is a type of chronic neurodegenerative disorder. There is an ongoing need for the development of new medications to address this illness. Loureirin C is known to have a protective impact on neurological disorders. Nonetheless, its specific function in Parkinson's Disease (PD) has yet to be fully understood. In this study, we examined the effects of Loureirin C in a cellular model of PD. The PD cell model was established by treating PC-12 cells with 6-hydroxydopamine (6-OHDA). We revealed that Loureirin C promoted the growth of 6-OHDA-treated PC-12 cells. In addition, Loureirin C suppressed the apoptosis of 6-OHDA-treated PC-12 cells and alleviated ferroptosis. Further, Loureirin C improved mitochondrial membrane potential in 6-OHDA-treated PC-12 cells. Mechanically, Loureirin C mediated Nrf2 pathway. Accordingly, Loureirin C not only inhibits ferroptosis but also apoptosis in the 6-OHDA-induced PD cell model, leading us to consider the potential value of Loureirin C in the treatment of PD.</div></div>","PeriodicalId":23201,"journal":{"name":"Tissue & cell","volume":"93 ","pages":"Article 102721"},"PeriodicalIF":2.7000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tissue & cell","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0040816625000011","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ANATOMY & MORPHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Parkinson's disease (PD) is a type of chronic neurodegenerative disorder. There is an ongoing need for the development of new medications to address this illness. Loureirin C is known to have a protective impact on neurological disorders. Nonetheless, its specific function in Parkinson's Disease (PD) has yet to be fully understood. In this study, we examined the effects of Loureirin C in a cellular model of PD. The PD cell model was established by treating PC-12 cells with 6-hydroxydopamine (6-OHDA). We revealed that Loureirin C promoted the growth of 6-OHDA-treated PC-12 cells. In addition, Loureirin C suppressed the apoptosis of 6-OHDA-treated PC-12 cells and alleviated ferroptosis. Further, Loureirin C improved mitochondrial membrane potential in 6-OHDA-treated PC-12 cells. Mechanically, Loureirin C mediated Nrf2 pathway. Accordingly, Loureirin C not only inhibits ferroptosis but also apoptosis in the 6-OHDA-induced PD cell model, leading us to consider the potential value of Loureirin C in the treatment of PD.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

loreirin C抑制6-羟多巴胺诱导的帕金森模型铁下垂和细胞凋亡。

帕金森病（PD）是一种慢性神经退行性疾病。目前需要开发新的药物来治疗这种疾病。已知Loureirin C对神经系统疾病具有保护作用。尽管如此，其在帕金森病（PD）中的具体功能尚未完全了解。在这项研究中，我们检测了Loureirin C在PD细胞模型中的作用。用6-羟基多巴胺（6-OHDA）处理PC-12细胞，建立PD细胞模型。我们发现，Loureirin C促进了6- ohda处理的PC-12细胞的生长。此外，Loureirin C抑制6- ohda处理的PC-12细胞凋亡，减轻铁下垂。此外，Loureirin C改善了6- ohda处理的PC-12细胞的线粒体膜电位。在机械上，Loureirin C介导Nrf2通路。因此，在6- ohda诱导的PD细胞模型中，Loureirin C不仅可以抑制铁凋亡，还可以抑制细胞凋亡，这让我们考虑了Loureirin C在PD治疗中的潜在价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Tissue & cell 医学-解剖学与形态学

CiteScore

3.90

自引率

0.00%

发文量

234

期刊介绍： Tissue and Cell is devoted to original research on the organization of cells, subcellular and extracellular components at all levels, including the grouping and interrelations of cells in tissues and organs. The journal encourages submission of ultrastructural studies that provide novel insights into structure, function and physiology of cells and tissues, in health and disease. Bioengineering and stem cells studies focused on the description of morphological and/or histological data are also welcomed. Studies investigating the effect of compounds and/or substances on structure of cells and tissues are generally outside the scope of this journal. For consideration, studies should contain a clear rationale on the use of (a) given substance(s), have a compelling morphological and structural focus and present novel incremental findings from previous literature.